Biotechnology startups often promise to "drug the undruggable," but few have embraced that challenge as boldly as Proxima Biosciences.

Patent expiration is the single largest value driver in pharmaceutical royalty valuation, yet most market participants use oversimplified assumptions. Rigorous

The GTN Landscape: A $356 Billion Problem Enters a New Era "Gross-to-net" (GTN) refers to the difference between

In Silico Medical Device Regulation Reaches Global Inflection Point The regulatory landscape for computational modeling in medical device development has

The second week of 2026—dominated by the 44th Annual J.P. Morgan Healthcare Conference in San Francisco—delivered over $12 billion in announced transaction value despite the conspicuous absence of any transformational M&A

Royalty financings in pharma and biotech are increasingly "stacked" – multiple monetizations and debt facilities layered on identical royalty

Executive Summary Droia Ventures is a Belgium-based venture capital firm that has established itself as one of Europe's

No, they're not selling disco balls—but DISCO Pharmaceuticals certainly knows how to shine in biotech. The company

Repayment caps have emerged as the defining structural element of synthetic royalty transactions, appearing in 72% of deals from 2019–

The commercialization of academic research has become one of the most consequential—yet least understood—dynamics in global pharmaceutical markets.